In an individual patient data meta-analysis (n = 9524) by the International Breast Cancer Study Group (IBCSG) including patients with early BC with no prior systemic therapy, the 10-year cumulative incidence of BM was higher among women with HER2-positive disease (6.8% versus 3.5%; p < 0.01) [3]. This evidence concerns the gene ERBB2 and breast carcinoma.